Specific Cytotoxicity of Targeted 177Lu and 212Pb-Based Radiopharmaceuticals
暂无分享,去创建一个
E. N. Lebedenko | A. A. Shul'ga | A. Kaprin | M. Vorontsova | D. Chuvilin | P. Shegai | A. Pankratov | K. Kokov | B. Egorova | G. Proshkina | E. Nemtsova | A. Plyutinskaya | S. Deev | V. A. Golovachenko
[1] A. Schulga,et al. Comparative Evaluation of Two DARPin Variants: Effect of Affinity, Size, and Label on Tumor Targeting Properties. , 2019, Molecular pharmaceutics.
[2] P. Geramifar,et al. Design, preparation and biological evaluation of a 177Lu-labeled somatostatin receptor antagonist for targeted therapy of neuroendocrine tumors. , 2019, Bioorganic chemistry.
[3] R. Y. Yakovlev,et al. Radiopharmaceuticals Based on Alpha Emitters: Preparation, Properties, and Application , 2018, Physics of Atomic Nuclei.
[4] E. N. Lebedenko,et al. Targeted Bifunctional Proteins and Hybrid Nanoconstructs for Cancer Diagnostics and Therapies , 2017, Molecular Biology.
[5] J. Berlin,et al. Phase 3 Trial of 177Lu‐Dotatate for Midgut Neuroendocrine Tumors , 2017, The New England journal of medicine.
[6] K. Howard,et al. Albumin-based drug delivery: harnessing nature to cure disease , 2016, Molecular and Cellular Therapies.
[7] H. Jadvar,et al. Targeted Radionuclide Therapy: Practical Applications and Future Prospects , 2016, Biomarkers in cancer.
[8] P. Albertsson,et al. The Potential and Hurdles of Targeted Alpha Therapy – Clinical Trials and Beyond , 2013, Front. Oncol..
[9] A. Plückthun,et al. Structural basis for eliciting a cytotoxic effect in HER2-overexpressing cancer cells via binding to the extracellular domain of HER2. , 2013, Structure.
[10] Guy Georges,et al. The emerging role of new protein scaffold-based agents for treatment of cancer. , 2013, Cancer genomics & proteomics.
[11] S. M. Deyev,et al. Modern Technologies for Creating Synthetic Antibodies for Clinical application , 2009, Acta naturae.
[12] Vladimir Tolmachev,et al. Radionuclide therapy of HER2-positive microxenografts using a 177Lu-labeled HER2-specific Affibody molecule. , 2007, Cancer research.
[13] J. Carlsson,et al. Tumor imaging using a picomolar affinity HER2 binding affibody molecule. , 2006, Cancer research.
[14] A. Plückthun,et al. Engineering novel binding proteins from nonimmunoglobulin domains , 2005, Nature Biotechnology.